Faculty members listed are those who have contributed to past or ongoing efforts with CMOD.

Eric Abadie, M.D., Director, Therapeutics Evaluation, AFSSAPS, European Medicines Agency (EMEA) Paris, France

Petar Alaupovic, Ph.D., Head, Lipid and Lipoprotein Laboratory, Oklahoma Medical Research Foundation

Christine Albert, M.D., MPH, Director, Center for Arrhythmia Prevention, Harvard Medical School Boston, MA

Michelle A. Albert, M.D., M.P.H. Assistant Professor of Medicine, Brigham and Women’s Hospital Harvard Medical School Boston, MA

Jonathan Allis, Ph.D. Global Head, Imaging Technology General Electric Healthcare

Pierre Amarenco, M.D. Department of Neurology and Stroke Centre Bichat - Claude Bernard University Hospital and Medical School Paris, France

Todd Anderson, M.D. , Director, Foothills Interventional Cardiology Research, Calgary, Alberta

Lawrence J. Appel, M.D, M.P.H. Professor of Medicine, Epidemiology and International Health (Human Nutrition) Johns Hopkins Medical Institutions Baltimore, MD

Naomi Aronson, Ph.D., Executive Director Technology Evaluation Center, Blue Cross and Blue Shield Association Chicago, IL

Robert Balaban, PhD, Director, Laboratory of Cardiac Energetics, NHLBI, NIH

Ruth Barrington, PhD, Chief Executive Officer, Molecular Medicine Ireland, Dublin, Ireland

Thomas Barry, PhD, Molecular Diagnostics Research Group, National University of Ireland, Galway

Philip Barter, The Heart Research Institute Sydney, Australia

Steven R. Bauer, PhD, FDA, Center for Biologics Evaluation & Research, OCTG

Rob Beanlands, MD, Chief, Cardiac Imaging Director, National Cardiac PET Centre, U. Ottawa Heart Institute

Guy Beaulieu, M.D., Science Advisor, Health Canada

Philippe Bedard, MD, FRCP(C), Division of Medical Oncology Drug Development Program, Princess Margaret Hospital University of Toronto

Colin Berry, BSc., Ph.D. Cardiovascular MRI / CV Intervention Program NHLBI, National Institutes of Health Bethesda, MD

Donald M. Black, MD, MBA, Chief Medical Officer, DalCor UK Pharma, Ltd.

Sandra E. Black, MD, FRCP(C), Brill Chair in Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Canada

Melanie Blank, MD, Medical Reviewer, Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, United States Food and Drug Administration (FDA)

Stefan Blankenberg, M.D. Department of Medicine University of Mainz Mainz, Germany

Suzanne Bracken, PhD, Program Officer in Translational Research, Molecular Medicine Ireland

Eric P. Brass, MD, PhD, Prof of Med, Harbor-UCLA Medical Center

Eugene Braunwald, MD, Professor of Medicine, Harvard Medical School

H Bryan Brewer, MD, Medstar Research Institute

B. Greg Brown, M.D., Ph.D. University of Washington Medical Center

David G. Brown, Ph.D., Center for Devices and Radiological Health, FDA

W. Virgil Brown, M.D. Charles Howard Candler Professor of Medicine Emory University School of Medicine Atlanta, GA

Michael A. Brownlee, MD, Albert Einstein College of Medicine

Diarmuid Cahalane, Founder of Open Innovation Partners Ltd, Cork, Ireland

Dolores Cahill, PhD, Professor of Translational Science, University College Dublin, Dublin, Ireland

Robert Califf, MD, Director, Duke Translational Medicine Institute

Gregory Campbell, Ph.D., Director, Division of Biostatistics, Center for Devices and Radiological Health, U.S. Food and Drug Administration

Chris Cannon, M.D. Brigham and Women’s Hospital

Laure Cloarec-Blanchard, MD, Servier International

Patricia Cole, MD, PhD, Director, Global Head, Imaging Biometrics, Esai Medial Research, Inc.

Helen Colhoun, Professor of Public Health, University of Dundee, Scotland

Eric Colman, MD, Deputy Director, Division of Metabolism and Endocrine, Center for Drug Evaluation and Research, FDA

Carolyn C. Compton, M.D., Ph.D., Director, Office of Biorepositories and Biospecimen Research, National Cancer Institute

Gloria Crispino, PhD, Clinicial Trial Statistician, Institute of Technology Tallaght, Dublin, Ireland

Janet Dancey, MD., Director, National Cancer Institute of Canada, Clinical Trials Group, Kingston, Ontario

Simhan Danthi, PhD., Division of Cardiovascular Sciences, NHLBI, NIH

Jean Davignon, M.D. Director Hyperlipidemia and Athero Research Clinical Research Institute of Montreal Professor of Medicine, University of Montreal Montreal, Quebec

Jill Davies, Director of Genetics, Medcan Clinic, Toronto, Ontario

Pim De Feyter, M.D., Professor of Non-invasive Cardiac Imaging, Erasmus University, Rotterdam, the Netherlands

James de Lemos, M.D. Associate Professor and CCU Director University of Texas-Southwestern Medical School Dallas, TX

Clarissa Desjardins, PhD, CEO, Center of Excellence in Personalized Medicine

Marcelo Di Carli, MD, Chief, Nuclear Medicine, Brigham and Women's Hospital

Jay M. Edelberg, M.D., Ph.D. Director, Cardiovascular Biomarkers Clinical Pharmacology & Discovery Medicine GlaxoSmithKline

Elizabeth Eisenhauer, M.D., Chair, Research Action Group, Canadian Partnership Against Cancer

Benjamin Eloff, PhD, Office of the Commissioner, US FDA

Jamie Engert, M.D., Genomic Medicine Center, Chicoutimi Hospital

Zahi A. Fayad, PhD, Professor of Medicine, Mount Sinai School of Medicine

Mark Ferguson, PhD, Director General, Science Foundation Ireland

Giora Feuerstein, M.D. Assistant Vice President Head, Discovery Translational Medicine Wyeth Research

Robert Fiorentino, MD, Medical Reviewer, Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, United States FDA

Brian C. Foster, Therapeutic Products Directorate, Health Products and Food Branch, Health Canada

Felix W. Frueh, Ph.D. Office of Clinical Pharmacology Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Springs, MD

Bruce Furie, M.D. Professor of Medicine Harvard Medical School Boston, MA

Brandon D. Gallas, NIBIB/CDRH Laboratory for the Assessment of Medical Images, FDA, Center for Devices and Radiological Health, Office of Science and Engineering Labs, Division of Imaging and Applied Math

Jean-Jacques Garaud, MD, Head of Global Drug Development, F. Hoffmann-La Roche Ltd.

Alan J. Garber, M.D., Ph. D. Professor, Medicine, Biochemistry, Molecular and Cellular Biology Baylor College of Medicine Houston, TX

Peter Gardiner, Vice President, Medical Affairs & Senior Medical Officer at BG Medicine

Daniel Gaudet M.D., PhD., CRC in preventive genetics, Associate professor of medicine, Université de Montréal, Lipid Clinic, Chicoutimi Hospital

Robert Gerszten, M.D. Professor of Medicine Massachusetts General Hospital Boston, MA

Marcie Glicksman, PhD., Co-Director, Laboratory for Drug Discovery in Neurodegeneration (LDDN), Harvard NeuroDiscovery Center

Anne Goodbody, PhD., Chief Regulatory Officer, Centre for Probe Development and Commercialization, Hamilton, Ontario

Federico Goodsaid, Ph.D. Office of Clinical Pharmacology Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring, MD

Michael Graham, Ph.D., MD, President, Society of Nuclear Medicine

Mark Grant, MD, Tech Evaluation Center, Blue Cross Blue Shield Association

Philip Greenland, M.D. Harry W. Dingman Professor, Preventive Medicine Executive Associate Dean for Clinical and Translational Research Feinberg School of Medicine-Northwestern University

Steven Gutman, MD, Director, Office of In Vitro Diagnostics, FDA

Rory Hachamovitch, M.D., M.Sc., Director of Nuclear Cardiology, University of Southern California Medical Center, Los Angeles, CA

Steven M. Haffner, M.D. Professor of Medicine University of Texas Health Centers San Antonio, TX

Patricia Harlow, Ph.D., Division of Cardiovascular and Renal Products, CDER, FDA

Robert A. Harrington, M.D. Professor of Medicine Duke University Medical Center Durham, NC

Thomas Hatsukami, M.D., Co-Director, Vascular Imaging Laboratory, University of Washington, Seattle, WA

Stanley Hazen, M.D., Ph.D., Director, Center for Cardiovascular Diagnostics and Prevention Section Head, Preventive Cardiology and Rehabilitation, Cleveland Clinic, Cleveland, OH

Jay Heinecke, M.D., Professor of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA

Therese Heinonen, DVM, Director, MHI Coordinating Center and Co-Founder/Exec Dir., CMOD, USA

Sharon Hertz, M.D., Deputy Director Anesthesia, Analgesia, and Rheumatology Products CDER

Karen A. Hicks, MD, Medical Officer, CDER, US FDA

Chris Howard, Solution Architect, IBM Innovation Centre, Dublin, Ireland

Thomas HudsonM.D., President and Scientific Director, Ontario Institute for Cancer Research, Toronto, CA

Patrice Hugo, PhD., Chief Scientific Officer Clearstone Central Laboratories

Ilan Irony, MD, Clinical Team Leader, DMEP, OND, CDER, US FDA

Narayanan Iyer, BSc, LLB, BCL, Health Canada

Seigo Izumo, M.D., Senior Vice President, Cardiovascular Therapeutics, Gilead Sciences, Inc.

Allan S. Jaffe, M.D. Professor of Medicine Mayo Clinic College of Medicine Rochester, MN

Hylton V. Joffe, MD, Metabolism and Endocrine, CDER, US FDA

Dominique Johnson, PhD, Director, Montreal Health Innovations Coordinating Center (MHICC)

Koen Kas, PhD, Professor, University Ghent, CSO, Pronota, Ghent, Belgium

John J.P. Kastelein, M.D., Ph.D., Department of Vascular Medicine, Academic Medical Center, University of Amsterdam

Cormac Kilty, PhD, Chief Technical Officer, EKF Diagnostics, London, England

Agnes Klein, MD, Director, Center for Evaluation of Radiopharmaceuticals and Biotherapeutics, Health Canada, Ottawa, Canada

Michael Klimas, Ph.D. Executive Director, Imaging Franchise Lead Merck & Co., Inc.

Christoph Koenen, Vice President, Global Medical Affairs, Bristol-Myers Squibb Co.

Wolfgang Koenig, MD, Professor of Medicine and Cardiology, University of Ulm Medical Centre, Ulm, Germany

Ronald M. Krauss, M.D. Senior Scientist and Director, Atherosclerosis Research Children’s Hospital Oakland Research Institute University of California Berkeley, CA

Lewis H. Kuller, M.D., Dr.P.H., Chair, Department of Epidemiology, University of Pittsburgh

Philippe L’Allier, M.D. Associate Director, QCA Core Labs Montreal Heart Institute Montreal, Quebec Canada

Reijo Laaksonen, MD, PhD, Chief Med Officer and Co-Founder, Zora Biosciences, Espoo, Finland

Hanno Langen, PhD, Global Head of Protein and Metabolite Technologies, Hoffmann-LaRoche, Basel, Switzerland

Michael S. Lauer, MD, FACC, FAHA, Director, Division of Cardiovascular Sciences (DCVS) National Heart, Lung, and Blood Institute (NHLBI)

Jeffrey M. Leiden, MD PhD, Managing Director, Clarus Ventures LLC

Lawrence A. Leiter, MD, FRCPC, FACP, Head, Division of Endocrinology & Metabolism, St. Michael’s Hospital, Professor of Medicine & Nutritional Sciences, University of Toronto

Claude Lenfant, M.D. Former Director National Heart, Lung, and Blood Institute

Andrew Levey, MD. Chief, Division of Nephrology, Tufts Medical Center

Daniel Levy, MD Director, Framingham Heart Study Director, Center for Population Studies National Heart, Lung, & Blood Institute Bethesda, MD

Timao Li, Ph.D. Acting Manager, Cardiovascular-Renal Division Bureau of Cardiology, Allergy and Neurological Sciences Therapeutic Products Directorate Health Canada Ottawa, Ontario Canada

Peter Libby, MD, Mallinckrodt Professor of Medicine, Harvard Medical School, Chief of Cardiovascular Medicine, Brigham & Women’s Hospital

Robyn R. Lim, Ph.D., Scientific Advisor, Office of Legislative and Regulatory Modernization, Health Canada

Joao Lima, M.D. Associate Professor of Medicine and Radiology Johns Hopkins Medical School Baltimore, MD

Jonathan R. Lindner, M.D. Associate Professor of Medicine and Associate Chief for Education Cardiovascular Division Oregon Health & Science University Portland, OR

Lance Liotta, MD, PhD, The Center for Applied Proteomics and Molecular Medicine, George Mason University

Ray Lipicky, M.D. Former Director U.S. Food and Drug Administration, Director, LIPICKY LLC

Peter Liu, M.D., Ph.D., Director, Institute of Circulatory and Respiratory Health, Canadian Institutes of Health Research (CIHR), Professor of Medicine, University of Toronto

Eva Lonn, MD, MSc, FRCPC, FACC, Professor of Medicine, McMaster University

Klas Malmberg, MD, PhD, FESC, Karolinska Institutet, Stockholm, Sweden, Clinical Science Leader, F. Hoffman-La Roche Ltd, Basel, Switzerland

G. B. John Mancini, M.D. Professor of Medicine, Division of Cardiology Director, CV Imaging Core Lab Vancouver Hospital Head, Department of Medicine, University of B.C.

Elizabeth Mansfield, Ph.D. Senior Policy Analyst Office of In Vitro Diagnostic Device Evaluation and Safety, Center for Devices and Radiological Health US FDA

Catriona McMahon, MD, Vice-President, Medical Affairs, AstraZeneca Canada Inc.

Jessica L. Mega, M.D., M.P.H., Associate Professor, Harvard Medical School and Associate Physician in Carddiovascular Medicine, Brigham and Women's Hospital

David O. Meltzer, M.D., Ph.D. Director of the Center for Health and Social Sciences Department of Medicine and Dept. of Economics University of Chicago

George A. Mensah, M.D., Chief Medical Officer, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC)

Michele Mercuri, MD, PhD, Vice President, Daiichi-Sankyo Pharma Development

Pierre Meulien, PhD, President and Chief Executive Officer, Genome Canada

George Mills, MD, VP, Medical Imaging Consultant, Perceptive Informatics

Gary F. Mitchell, M.D. Cardiovascular Engineering, Inc. Waltham, MA

Clemens Mittmann, M.D. Federal Institute for Drugs and Medical Devices (BfArM) Bonn, Germany

Jacques Mizrahi, M.D., Head Clinical Research and Exploratory Development Metabolic Diseases, F. Hoffmann-La Roche Ltd.

Alan Moody, Radiologist in Chief, Sunnybrook Health Sciences Centre

Vincent Mooser, MD., Medical Genetics/Clinical Pharmacology And Discovery Medicine, GlaxoSmithKline

David A. Morrow, M.D., MPH TIMI Study Group Cardiovascular Division Brigham and Women’s Hospital Boston, MA

Allison Mueller, Neurology Group Leader Global Regulatory Affairs GE Healthcare Medical Diagnostics R&D

C. Daniel Mullins, PhD, Professor, Pharmacoeconomics, University of Maryland

Elizabeth Nabel, M.D., Director, National Heart, Lung and Blood Institute, National Institutes of Health

Ilaria Nardello, Ph.D., National Coordinator, the Marine Institute, Dublin, Ireland

Steve Nissen, M.D., Chairman, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

Irene Nunes, OD, PhD, Merck Research Laboratories

Christopher O'Donnell, M.D. Senior Advisor to the Director for Genome Research Associate Director of the Framingham Heart Study NHLBI, National Institutes of Health

Terri O’Grady, RPh, PhD., Canadian Agency for Drugs & Technology in Health

Daniel H. O’Leary, M.D., Chairman, Department of Radiology, New England Medical Center

Oye Olukotun, MD, CEO, CardioVax Inc.

Pat O’Mahony, DVM, MBA, Executive Director, Irish Medicines Board, Chairman, European Medicines Agency (EMA), Dublin, Ireland

David G. Orloff, M.D., Former Director, Division of Metabolism and Endocrinology, FDA and Vice President, Medpace Inc.

James Otvos, PhD., Chief Scientific Officer, LipoScience, Inc., Adjunct Professor, Department of Biochemistry, North Carolina State University

Pamela Ouyang, M.D., Johns Hopkins Bayview Medical Center

Mary Parks, MD, Director, Metabolism and Endocrine, CDER, US FDA

Gerard Pasterkamp, MD, PhD, Chief Scientific Officer, Cavadis; Experimental Cardiology Laboratory, University Medical Center Utrecht, the Netherlands

Michael Perelman, M.D. Vice President, Global Project Mgmt Schering-Plough Research Institute

Marc Pfeffer, M.D., Ph.D. Professor of Medicine Harvard Medical School Brigham and Women’s Hospital Boston, MA

Michael S. Phillips, Ph.D. Director of Pharmacogenomics Genome Quebec Montreal, Quebec

Hubert Pouleur, MD, PhD, Vice President, Cardiovascular-Metabolic Disease Strategy, Pfizer Inc, New York, New York, USA

Robert Powell, PharmD Director, Pharmacometrics Office of Clinical Pharmacology Center for Drug Evaluation and Research US Food and Drug Administration

Aidan Power, Vice President and Head of PharmaTherapeutics Precision Medicine, Pfizer Inc.  

Margaret Prescott, M.D. Metabolic and Cardiovascular Research Department Novartis Institute for Biomedical Research Summit, NJ

Joel Raichlen, MD, Senior Director, AstraZeneca

Daniel Rader, M.D. University of Pennsylvania School of Medicine

Paolo Raggi, M.D. Tulane University School of Medicine

Gurvaneet Randhawa, MD, Agency for Healthcare Research and Quality

Patricia Reilly, Member of the Cabinet of Máire Geoghegan-Quinn, European Commissioner for Research, Innovation and Science, Dublin, Ireland

Alan Remaley, MD, PhD, Laboratory of Lipoprotein Metabolism, NHLBI, NIH

Paul Ridker, MD, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital

Dwaine Rieves, MD, Director, Medical Imaging and Hematology, CDER, US FDA

Eric Rimm, Sc.D. Associate Professor of Epidemiology and Nutrition Harvard School of Public Health Boston, MA

John Rioux, Ph.D. The Laboratory of Genetics and Genomic Medicine of Inflammation Université de Montréal and Montreal Heart Institute

Robert Roberts, MD, FRCP(C), MACC, Director, Ruddy Canadian Cardiovascular Genetics Centre, President & CEO, University of Ottawa Heart Institute

Yves Rosenberg, MD, MPH, Acting Branch Chief, Atherothrombosis and Coronary Artery Disease Branch, NHLBI, NIH

Robert Rosenson, MD, Professor of Medicine, Mt. Sinai School of Medicine

Amy E. Rudolph, Ph.D. Clinical Director Global Medical CV Metabolic Endocrine Pfizer, Inc

Kerry-Anne Rye, The Heart Research Institute, Sydney, Australia

Frank Sacks, M.D. Professor of Cardiovascular Disease Prevention Department of  Nutrition Harvard School of Public Health Boston, MA

Patrice Sarrazin, PhD. Senior Scientific Evaluator In Vitro Diagnostic Devices Medical Devices Bureau Therapeutic Product Directorate, Health Canada

William J. Sasiela, Ph.D. Chief Medical Officer Aegerion Pharmaceuticals, Inc.

Ernst Schaefer, M.D. Director, Lipid Metabolism Laboratory Tufts University Boston, MA

Carina Schmidt, MSc, Chief Executive Officer, Athera Biotechnologies, Stockholm, Sweden

Daniel Schultz, M.D. Director, Center for Devices and Radiological Health US Food and Drug Administration Rockville, MD

Sonia Skarlatos, MD, Deputy Dir., Division of CV Sciences, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA

Daniel M. Skovronsky, MD, PhD, Founder and CEO Avid Radiopharmaceuticals

David M. Smalley, PhD, Biomedical Research Facility Cardiovascular Research Center University of Virginia

J. David Spence, M.D. Director, Stroke Prevention and Athero Research Centre Robarts Research Institute London, Ontario, CANADA

George Steiner, M.D. Toronto General Hospital

Norman Stockbridge, MD, Director, Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, FDA

Anders Svensson, MD, Head, Clinical Development, Metabolism, F. Hoffman-La Roche

Alan Tall, M.D., Tiden Weger Bieler Professor of Medicine, Columbia University Medical Center, New York, NY

Jean-Claude Tardif, MD, Director, Montreal Heart Institute (MHI) Research Center; Prof. of Medicine, U of Montreal, Canada Research Chair in translational and personalized medicine

Ahmed Tawakol, MD, Professor of Medicine, Massachusetts General Hospital

Allen J. Taylor, MD, Professor of Medicine, Georgetown University, Department of Medicine, Washington Hospital Center

Doris Taylor, PhD, Director of the Center for Cardiovascular Repair, Stem Cell Institute, University of Minnesota

Robert J. Temple, MD, Deputy Director of Clinical Science, Center for Drug Evaluation and Research, United States FDA

Douglas Throckmorton, MD, Deputy Center Director, Center for Drug Evaluation and Research, United States FDA

Paula R. Trumbo, Ph.D. Team Leader, Nutrition Science Evaluation Center for Food Safety and Applied Nutrition US Food and Drug Administration College Park, MD

Sotirios Tsimikas, M.D., Director, Vascular Medicine, Associate Professor Of Medicine, University of California, San Diego

James E. Udelson, M.D., Chief, Division of Cardiology; Director, Nuclear Cardiology Laboratory; Professor, Tufts University School of Medicine

Roger Ulrich, Ph.D., Fellow ATS, Chief Development Officer, Calistoga Pharmaceuticals Inc. Seattle, Washington

Spiros Vamvakas, Head of Section for Scientific Advice, European Medicines Agency

John Wagner, MD, Ph.D. Director, Clinical Pharmacology Merck & Co., Inc.

Karin Wåhlander, PhD, Vice President for Translational Science, AstraZeneca, Sweden

Marc Walton, MD, PhD, Associate Director, Office of Translational Sciences, Center for Drug Evaluation and Research, United States FDA

G. Russell Warnick, M.S., MBA, Chief Scientific Officer, Sr. VP for Laboratory Operations, Berkeley HeartLab, Inc.

Robert Wasserman, M.D., Vice President and Personalized Healthcare Strategy, F. Hoffmann-La Roche Ltd.

David D. Waters, M.D., Professor Emeritus, University of California, San Francisco

Ralph Weissleder, M.D., Ph.D. Director, Center for Molecular Imaging Research Professor of Radiology, Harvard Medical School Boston, MA

Gerald Willett, MD, Reproductive and Urologic Drug Products, CDER, US FDA

Samuel Wright, PhD, Director, Cardiovascular Therapeutics, CSL Ltd.

Helen Wu, PhD., Research Leader, Genomics & Oncology, Roche Molecular Systems, Inc.

James J. Zhang, M.D., Ph..D., MBA Global Clinical Development Siemens Molecular Imaging, Inc Siemens Medical Solutions USA

Issam Zineh, PharmD, MPH, Associate Director for Genomics, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, United States FDA

Bram Zuckerman, M.D. Director, FDA Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health (CDRH)